Cardiac tissue engineering using human stem cell-derived cardiomyocytes for disease modeling and drug discovery

Area of Science:

• Biomedical Engineering
• Cardiology
• Stem Cell Biology

Background:

• Cardiovascular disease (CVD) presents a significant global health challenge, with high mortality due to irreversible heart muscle damage.
• Current treatments for damaged myocardium are limited, necessitating the development of novel therapeutic strategies.

Purpose of the Study:

• To evaluate human engineered cardiac tissues (hECT) as a preclinical model for studying myocardial physiopathology.
• To explore the potential of hECT in the development and screening of new therapies for CVD.

Main Methods:

• Generation of hECT using cardiomyocytes from human embryonic stem cells and induced pluripotent stem cells.
• Characterization of hECT structural and functional properties.
• Assessment of hECT responses to compounds affecting cardiac function.

Main Results:

• hECT exhibit structural and functional characteristics mimicking natural human myocardium.
• These tissues demonstrate dose-related responses to compounds with known chronotropic, inotropic, and arrhythmogenic effects.
• hECT provide a biomimetic 3D environment superior to traditional in vitro models.

Conclusions:

• hECT represent a promising in vitro model for cardiovascular research.
• The biomimetic nature of hECT facilitates the study of myocardial diseases.
• hECT hold potential for advancing preclinical drug development and therapy screening for CVD.